These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33912014)

  • 1. Nucleolin Rescues TDP-43 Toxicity in Yeast and Human Cell Models.
    Peggion C; Massimino ML; Stella R; Bortolotto R; Agostini J; Maldi A; Sartori G; Tonello F; Bertoli A; Lopreiato R
    Front Cell Neurosci; 2021; 15():625665. PubMed ID: 33912014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Integrity of Nucleolin Is Required to Suppress TDP-43-Mediated Cytotoxicity in Yeast and Human Cell Models.
    Peggion C; Massimino ML; Pereira D; Granuzzo S; Righetto F; Bortolotto R; Agostini J; Sartori G; Bertoli A; Lopreiato R
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies.
    Cascella R; Capitini C; Fani G; Dobson CM; Cecchi C; Chiti F
    J Biol Chem; 2016 Sep; 291(37):19437-48. PubMed ID: 27445339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PABPN1 suppresses TDP-43 toxicity in ALS disease models.
    Chou CC; Alexeeva OM; Yamada S; Pribadi A; Zhang Y; Mo B; Williams KR; Zarnescu DC; Rossoll W
    Hum Mol Genet; 2015 Sep; 24(18):5154-73. PubMed ID: 26130692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis?
    Vanden Broeck L; Callaerts P; Dermaut B
    Trends Mol Med; 2014 Feb; 20(2):66-71. PubMed ID: 24355761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoplasmic Expression of the ALS/FTD-Related Protein TDP-43 Decreases Global Translation Both
    Charif SE; Luchelli L; Vila A; Blaustein M; Igaz LM
    Front Cell Neurosci; 2020; 14():594561. PubMed ID: 33363456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis.
    Kwong LK; Uryu K; Trojanowski JQ; Lee VM
    Neurosignals; 2008; 16(1):41-51. PubMed ID: 18097159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct targeting of TDP-43, from small molecules to biologics: the therapeutic landscape.
    Francois-Moutal L; Scott DD; Khanna M
    RSC Chem Biol; 2021 Aug; 2(4):1158-1166. PubMed ID: 34458829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear transport dysfunction: a common theme in amyotrophic lateral sclerosis and frontotemporal dementia.
    Jovičić A; Paul JW; Gitler AD
    J Neurochem; 2016 Aug; 138 Suppl 1():134-44. PubMed ID: 27087014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin B12 Reduces TDP-43 Toxicity by Alleviating Oxidative Stress and Mitochondrial Dysfunction.
    Jeon YM; Kwon Y; Lee S; Kim S; Jo M; Lee S; Kim SR; Kim K; Kim HJ
    Antioxidants (Basel); 2021 Dec; 11(1):. PubMed ID: 35052586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies.
    Miguel L; Frébourg T; Campion D; Lecourtois M
    Neurobiol Dis; 2011 Feb; 41(2):398-406. PubMed ID: 20951205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From molecule to molecule and cell to cell: prion-like mechanisms in amyotrophic lateral sclerosis.
    Grad LI; Fernando SM; Cashman NR
    Neurobiol Dis; 2015 May; 77():257-65. PubMed ID: 25701498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [TDP-43 proteinopathies, toward understanding of the molecular pathogenesis].
    Hasegawa M; Nonaka T; Yamashita M; Kametani F; Arai T; Yoshida M; Hashizume Y; Tsuchiya K; Akiyama H
    Rinsho Shinkeigaku; 2009 Nov; 49(11):783-5. PubMed ID: 20030209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?
    Hergesheimer RC; Chami AA; de Assis DR; Vourc'h P; Andres CR; Corcia P; Lanznaster D; Blasco H
    Brain; 2019 May; 142(5):1176-1194. PubMed ID: 30938443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of ALS-Associated Genes
    Bajc Česnik A; Motaln H; Rogelj B
    Cells; 2020 Jul; 9(8):. PubMed ID: 32731393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [TDP-43 proteinopathies: ALS and frontotemporal dementias].
    Prudlo J
    Fortschr Neurol Psychiatr; 2009 Aug; 77 Suppl 1():S25-7. PubMed ID: 19685386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TDP-43-Mediated Toxicity in HEK293T Cells: A Fast and Reproducible Protocol To Be Employed in the Search of New Therapeutic Options against Amyotrophic Lateral Sclerosis.
    Lanznaster D; Bourgeais J; Bruno C; Hergesheimer RC; Thepault RA; Vourc'h P; Corcia P; Andres CR; Herault O; Blasco H
    Cells; 2019 Dec; 9(1):. PubMed ID: 31888078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rab1-dependent ER-Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS.
    Soo KY; Halloran M; Sundaramoorthy V; Parakh S; Toth RP; Southam KA; McLean CA; Lock P; King A; Farg MA; Atkin JD
    Acta Neuropathol; 2015 Nov; 130(5):679-97. PubMed ID: 26298469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The molecular mechanisms of intracellular TDP-43 aggregates].
    Nonaka T; Arai T; Hasegawa M
    Brain Nerve; 2009 Nov; 61(11):1292-300. PubMed ID: 19938686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Znf179 E3 ligase-mediated TDP-43 polyubiquitination is involved in TDP-43- ubiquitinated inclusions (UBI) (+)-related neurodegenerative pathology.
    Lee YC; Huang WC; Lin JH; Kao TJ; Lin HC; Lee KH; Lin HC; Shen CJ; Chang WC; Huang CC
    J Biomed Sci; 2018 Nov; 25(1):76. PubMed ID: 30404641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.